US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial

December 20, 2024 – Stockholm, Sweden – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, announces that the independent Data Safety Review Board that is monitoring the safety and efficacy of the current clinical study, has agreed to allow investigators to exceed the previously established maximum dose of 1.5 mg/kg/day in the ongoing second cohort of its clinical trial for BSG005. This decision was made following a request from the Principal Investigator, supported by compelling preliminary data, reflecting the

Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3

The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors has today, on December 5, 2024, relying on the authorization from the Annual General Meeting on June 14, 2024, resolved on a directed issue of 734,963 shares to such underwriters in the warrant program who have chosen to receive underwriting compensation in the form of newly issued shares in the Company (the "Compensation

Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3

The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors has today, on December 3, 2024, relying on the authorization from the Annual General Meeting on June 14, 2024, decided on a directed share issue of 6,348,670 shares (the "Directed Issue") to a number of investors ("the Underwriters"). The subscription price in the Directed Issue is SEK 0.49, which corresponds to the

Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3

Biosergen AB (”Biosergen” or the "Company") announces today the outcome of the exercise of warrants of series TO3, which were issued in connection with a rights issue in the Company during the first quarter 2024. In total, 91,701,328 warrants of series TO3 were exercised, corresponding to 100.0 percent of the total number of outstanding warrants of series TO3, for subscription of 91,701,328 shares at an exercise price of SEK 0.49 per share. Biosergen will receive approximately SEK 44.9 million before issuing costs through the exercise of the warrants of series TO3. Upon the exercise period

Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections

November 26, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, is pleased to announce that the first two patients in the second cohort of its ongoing proof-of-concept clinical trial for BSG005 has successfully begun treatment with BSG005. The patients are suffering from a severe infection caused by Aspergillus and Mucor Mycosis respectively. These two patients represent challenging cases where current antifungal treatments have proven ineffective due to resistance and renal impairment.“It is exciting to

The last day of trading with the warrants of series TO3 in Biosergen AB is today, November 26, 2024

Today, November 26, 2024, is the last day of trading with the warrants of series TO3 (the “Warrants”)in Biosergen AB (”Biosergen” or the "Company"). The exercise period for the warrants of series TO3 runs up until November 29, 2024. One (1) warrant of series TO3 entitles the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO3 is set to SEK 0.49 per share.If all the warrants of series TO3 are exercised, the Company will receive approximately SEK 44.9 million before issuing costs. For the Warrants not to expire without value, it

Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005

November 21, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, is pleased to announce the release of a fireside-chat-style video interview during the World Antimicrobial Resistance Awareness Week (WAAW). The video features the company’s CEO, Tine Olesen, in conversation with Dr. Pawan Kumar Singh, Principal Investigator of Biosergen’s ongoing proof-of-concept trial for BSG005. The video is now available on the company’s website: https://www.biosergen.net/investor-relations#Events,%20Presentations,%20Media“I

Biosergen has secured 100 percent of the warrants of series TO3 approximately SEK 44.9 million

Biosergen AB (”Biosergen” or the "Company") has received subscription commitments and top underwriting commitments totaling approximately SEK 44.9 million, corresponding to approximately 100 percent of the issue proceeds that the Company could raise through the exercise of warrants of series TO3 (the "Warrants"). The subscription commitments amount to approximately SEK 29.9 million, corresponding to 66.5 percent of the Warrants, and have been provided by Östersjöstiftelsen, CEO Tine Kold Olesen, CFO Niels Laursen, CMO Peder M. Andersen, and several major warrant holders. The top underwriting

The exercise price for the warrants of series TO3 in Biosergen AB has been determined to SEK 0.49

Biosergen AB (”Biosergen” or the "Company") completed a rights issue during the first quarter of 2024, consisting of shares and warrants of series TO3. The exercise price for the warrants of series TO3 corresponds to 70 percent of the volume-weighted average price in the Company’s share on Nasdaq First North Growth Market during the measurement period, which ran from and including November 4, 2024, up to and including November 15, 2024, however not higher than SEK 0.50 and not less than SEK 0.30. During the measurement period, the volume-weighted average price in the Company’s share was

BioStock: Biosergen discusses positive results in patients with deadly fungal infections

So far, the majority of patients involved in Biosergen’s proof-of-concept study for life-threatening fungal infections have been able to leave the hospital. This suggests the potential effect of BSG005 even at low doses. Moreover, the subscription period for the company’s TO3 warrants is approaching, which will take place between November 18 and 29.Watch the interview with CEO Tine Olesen at biostock.se: https://www.biostock.se/en/2024/11/biosergen-discusses-positive-results-in-patients-with-deadly-fungal-infections/This is a press release from BioStock - Connecting Innovation &

Biosergen publishes interim report for third quarter 2024

Friday November 8, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the third quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net)     BIOSERGEN HAS COMPLETED FIRST PATIENT COHORTThe most significant recent result for Biosergen is the successful completion of the treatment of the first cohort of patients in our clinical trial for BSG005. The early data are remarkable, with some patients achieving complete recovery at a low dose of BSG005, while others experienced significant

Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial

November 7, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announced that an independent Safety Review Committee has approved the continuation of dose escalation in its ongoing proof-of-concept trial for BSG005. Following a favorable review of safety data from the first cohort, a new cohort of five patients will soon begin treatment at an increased dose level.“We are encouraged by the Safety Review Committee’s positive review of BSG005’s safety profile in the initial cohort, and we look forward to

BioStock: Biosergen’s CEO: “I’m optimistic that we may cure patients”

Biosergen recently announced the completion of treatment for the first cohort of patients in its proof-of-concept trial for its antifungal drug candidate BSG005. Most patients improved significantly, reflecting BSG005’s potential as a life-saving therapy. The next step involves dose escalation for the upcoming cohort. Importantly, between November 18 and 29, shareholders can exercise the warrants TO3, which could add a maximum of approximately SEK 45 million to the company, funding it well through 2025.Read the interview with CEO Tine Olesen at biostock.se: https://www.biostock.se/en/

Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections

October 31, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the completion of treatment for the first cohort of patients in its proof-of-concept clinical trial for its antifungal drug-candidate BSG005. The cohort consisted of five patients: two completely recovered, two saw significant improvements, and one very sick patient passed away because of unrelated causes to BSG005. The trial is evaluating the company’s drug candidate, BSG005, as a rescue therapy for patients who have either failed

BioStock: Biosergen advances BSG005 antifungal drug candidate trial

Biosergen is advancing its drug candidate BSG005, designed as a rescue treatment for patients with invasive fungal infections. The company has enrolled the first cohort in their phase Ib Proof-of-Concept trial, with 5 out of a total of 15 patients included so far. Biosergen’s CEO, Tine Olesen, came to BioStock's studio to discuss this milestone,  the company’s financing and the next steps ahead.See the interview with CEO Tine Olesen at biostock.se: https://www.biostock.se/en/2024/10/biosergen-advances-bsg005-antifungal-drug-candidate-trial/This is a press release from BioStock -

Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial

October 7, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first five-patient cohort in its proof-of-concept clinical trial. The trial is evaluating the company’s drug candidate, BSG005, as a rescue therapy for patients who have failed previous standard-of-care antifungal treatments due to either lack of efficacy or safety or patients with mild to moderate kidney impairment.“We are thrilled to have filled the first cohort,” said Tine Olesen, CEO of Biosergen.

BioStock: Biosergen’s CEO: “The first patient regained his health”

In Biosergen’s Q2 report, the company  highlights the successful start of the phase Ib study with BSG005. The first patient with invasive fungal disease recovered and preserved both his lungs by avoiding surgery after being treated with BSG005, something the company describes as “very remarkable.” BioStock reached out to CEO Tine Olesen to learn more about this success and the company’s financial status.Read the interview with Tine Olesen at biostock.se:https://www.biostock.se/en/2024/09/biosergens-ceo-the-first-patient-regained-his-health/This is a press release from BioStock -

Biosergen publishes interim report for second quarter 2024

Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the second quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net)Biosergen have treated the first patient with BSG005 ” We got the final permission to start our first patient study in Q2 and shortly after we recruited the first patient. The patient was diagnosed with Mucormycosis (black fungus) which is one of the most difficult  invasive fungal infections to treat. The patient was treated for 28 days and recovered with

Biosergen have completed treatment of the first patient with BSG005

Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby announce the completion of treatment of the first patient with BSG005Invasive fungal infections represent a serious health threat, claiming 2.5 mill lives annually. There is growing resistance toward current therapy and the lack of broad-spectrum safe therapies has the WHO on high alert. It needs attention, and we need novel effective safe treatments. Biosergen is developing BSG005 designed to be safe, efficacious and broad-spectrum. We have been focusing on the starting our first patient trial in India. As

BioStock: Biosergen on dosing the first patient with life-threatening fungal disease

The first patient has been dosed in Biosergen’s clinical phase Ib trial with BSG005, intended as rescue therapy for invasive fungal infection to increase survival rates for these critically ill patients. Topline results are anticipated by year-end or early 2025. BioStock reached out to CEO Tine Kold Olesen to learn more about the latest achievement.Read the interview at biostock.se:https://www.biostock.se/en/2024/07/biosergen-on-dosing-the-first-patient-with-life-threatening-fungal-disease/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

First Patient in Biosergen Clinical Trial Treating with BSG005 for Life Threatening Fungal Infection

Stockholm, Sweden – July 12, 2024 – Biosergen AB (“Biosergen”) is pleased to announce that the first patient suffering from an invasive fungal infection has been dosed with BSG005 as rescue therapy.‘Today marks a significant milestone as the first patient has received the first dose of our lead candidate BSG005. The goal with the study is to increase survival rates for these very ill patients with difficult to treat fungal strains or/and with resistance to current antifungal treatment. There is a significant unmet medical need for the many millions of people infected with and dying from

Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB

Today, on June 14, 2024, the annual general meeting was held in Biosergen AB. A summary of the adopted resolutions follows below. All resolutions were adopted in accordance with the presented proposals, which are described in detail in the notice to the annual general meeting available on the Company’s website, www.biosergen.net.Resolution on adoption of accounts and allocation of the Company’s profits The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The

Biosergen to welcome two new board members based on election at the Annual General Meeting

Stockholm, Sweden – June 11, 2024 – Based on the change in ownership during successful capital raise earlier this year major shareholders in Biosergen AB (Biosergen) present a proposal for the election of the board of directors ahead of the annual general meeting 2024Ahead of the annual general meeting in Biosergen to be held on Friday, June 14, 2024, major shareholders propose changes to the current board composition. Major shareholders propose that  new member Anna Ljung is elected as chairperson of the board for the period until the end of the annual general meeting in 2025 and that

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe